受让方通过询价转让受让的股份，在受让后 6 个月内不得转让。 一、本次询价转让初步定价 （一）经向机构投资者询价后，初步确定的转让价格为 30.88 元/股。 （二）参与本次询价转让报价及申购的机构投资者家数为 21 家，涵盖了基 金管理公司、证券公司、合格境外机构投资者、私募基金管理人等专业机构投资 者。参与本次询价转让报价及申购的机构投资者合计有效认购股份数量为 10,190,000 股，对应的有效认购倍数为 1.01 倍。 证券代码：688136 证券简称：科兴制药 公告编号：2025-076 科兴生物制药股份有限公司 股东询价转让定价情况提示性公告 股东深圳科益医药控股有限公司（以下简称"出让方"）保证向科兴生物制 药股份有限公司（以下简称"公司"）提供的信息内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 根据 2025 年 9 月 15 日询价申购情况，初步确定的本次询价转让价格为 30.88 元/股。 1 经营。 特此公告。 科兴生物制药股份有限公司董事会 2025 ...

Core Insights - The animal vaccine sector saw a rise of 1.30%, ranking 9th among concept sectors, with 14 stocks increasing in value, led by TianKang Biological, BioShares, and Jinhe Biological, which rose by 8.20%, 7.17%, and 3.00% respectively [1][2] - The sector experienced a net inflow of 190 million yuan from main funds, with 10 stocks receiving net inflows, and 5 stocks exceeding 10 million yuan in net inflow, led by Hengtong Co. with 71.08 million yuan [2][3] Sector Performance - The animal vaccine sector's performance was highlighted by the following stocks: - Hengtong Co.: 2.41% increase, 4.20% turnover rate, 71.08 million yuan net inflow, 15.05% net inflow ratio - Jinhe Biological: 3.00% increase, 5.44% turnover rate, 30.31 million yuan net inflow, 10.35% net inflow ratio - Kanghua Biological: 2.14% increase, 4.54% turnover rate, 44.90 million yuan net inflow, 10.14% net inflow ratio [3][4] Stock Movements - The top gainers in the animal vaccine sector included: - TianKang Biological: 8.20% increase - BioShares: 7.17% increase - The stocks with the largest declines included: - Shenlian Biological: 1.51% decrease - Dongfang Biological: 1.31% decrease - Xianfeng Holdings: 1.24% decrease [1][4]

Core Viewpoint - The initial pricing for the share transfer of Kexing Pharmaceutical is set at 30.88 CNY per share, representing a 28% discount compared to the closing price of 42.81 CNY per share on the same day [1] Group 1 - Kexing Pharmaceutical announced that the initial pricing for the share transfer is 30.88 CNY per share based on the inquiry subscription situation as of September 15, 2025 [1] - A total of 21 institutional investors participated in the bidding and subscription, with a combined effective subscription quantity of 10.19 million shares, resulting in an effective subscription multiple of 1.01 times [1] - The total number of shares to be transferred is 10.06 million shares, which has been fully subscribed by the 21 institutional investors [1]

Core Points - The core viewpoint of the article is that Sinovac Biotech (科兴制药) has successfully completed a share transfer inquiry, with a determined price of 30.88 yuan per share and full subscription of the offered shares by institutional investors [2] Group 1 - Sinovac Biotech announced the inquiry transfer price of 30.88 yuan per share based on the subscription situation as of September 15, 2025 [2] - A total of 21 institutional investors participated in the bidding and subscription, with a combined effective subscription of 10,190,000 shares, resulting in an effective subscription multiple of 1.01 times [2] - The total number of shares to be transferred has been fully subscribed, with the preliminary determined transferees being 21 institutional investors, who will acquire a total of 10,062,800 shares [2]

Core Points - The core announcement is about Sinovac Biotech (688136.SH) planning to transfer 5% of its shares, equivalent to 10.0628 million shares, through a non-public offering to qualified institutional investors [1] Group 1: Share Transfer Details - The controlling shareholder, Shenzhen Keyi Pharmaceutical Holdings Co., Ltd. (referred to as "Keyi Pharmaceutical"), is initiating the share transfer due to its operational development needs [1] - The transfer will be organized by China International Capital Corporation (CICC), with a minimum transfer price set at 70% of the average stock price over the 20 trading days prior to the issuance of the subscription invitation [1] - Previously, Keyi Pharmaceutical completed a transfer of 6.0377 million shares in August, representing 3% of the total share capital, at a price of 36.70 yuan per share [1] Group 2: Institutional Participation - A total of 13 institutional investors, including ICBC Credit Suisse, Caitong Fund, and J.P. Morgan, successfully acquired shares in the previous transfer, which are subject to a six-month lock-up period [1]

Core Viewpoint - The shareholder Shenzhen Koyi Pharmaceutical Holdings Co., Ltd. plans to transfer 10,062,800 shares of Sinovac Biotech, accounting for 5.00% of the company's total share capital, for its own operational development needs [1][2]. Group 1: Share Transfer Details - The transfer is a non-public transfer and will not be conducted through centralized bidding or block trading, meaning it is not a secondary market reduction [2][3]. - The transferee must be an institutional investor with appropriate pricing capability and risk tolerance [2]. - As of September 12, 2025, Koyi Pharmaceutical holds 119,751,430 shares, representing 59.50% of the company [2]. Group 2: Previous Share Transfers - On July 30, 2025, Koyi Pharmaceutical had previously planned to transfer 6,037,717 shares, which accounted for 3.00% of the total share capital, also for funding needs [3]. - The transfer price for the previous transaction was set at 36.70 CNY per share, totaling approximately 221.58 million CNY [3]. - Koyi Pharmaceutical had reduced its holdings by 5,989,200 shares between June 26 and July 9, 2025, at prices ranging from 32.84 to 48.37 CNY per share, amounting to a total of approximately 220.99 million CNY [3][4]. Group 3: Company Financials and Future Plans - Sinovac Biotech was listed on the Shanghai Stock Exchange on December 14, 2020, with an initial public offering (IPO) price of 22.33 CNY per share, raising a total of 1.11 billion CNY [4]. - The actual net fundraising was 995 million CNY, which was 710 million CNY less than the originally planned amount of 1.705 billion CNY [4]. - The company is currently planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with relevant intermediaries [5].

Core Viewpoint - The announcement details a share transfer plan by Shenzhen Keyi Pharmaceutical Holdings Co., Ltd. to transfer 10,062,800 shares of Kexing Pharmaceutical, representing 5.00% of the total share capital, through a non-public inquiry transfer process [3][7]. Group 1: Share Transfer Details - The total number of shares to be transferred is 10,062,800, which accounts for 5.00% of the company's total share capital [3][7]. - The transfer is organized by China International Capital Corporation (CICC) and is not conducted through public trading methods [3][10]. - The receiving party must be an institutional investor with appropriate pricing capabilities and risk tolerance [3][10]. Group 2: Seller Information - The seller, Shenzhen Keyi Pharmaceutical, is the controlling shareholder of Kexing Pharmaceutical, with a shareholding exceeding 5% [3][4]. - The seller has confirmed that the shares are free from any transfer restrictions and have been released from lock-up [4][5]. Group 3: Pricing Mechanism - The minimum transfer price will not be lower than 70% of the average trading price of the company's shares over the 20 trading days prior to the issuance of the subscription invitation [8]. - The pricing determination will follow a priority system based on subscription price, quantity, and time of submission [9]. Group 4: Company Status - Kexing Pharmaceutical does not have any undisclosed operational risks or potential changes in control related to this share transfer [11]. - There are no other significant undisclosed matters concerning the company [11].

股东询价转让计划书 股东深圳科益医药控股有限公司（以下简称"科益医药"或"出让方"）保 证向科兴生物制药股份有限公司（以下简称"公司"或"科兴制药"）提供的信 息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确性 和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 本次拟参与科兴制药首发前股东询价转让（以下简称"本次询价转让"） 的股东为深圳科益医药控股有限公司； 出让方拟转让股份的总数为 10,062,800 股，占公司总股本的比例为 5.00%； 证券代码：688136 证券简称：科兴制药 公告编号：2025-075 科兴生物制药股份有限公司 本次询价转让为非公开转让，不通过集中竞价交易方式或大宗交易方式 进行，不属于通过二级市场减持。受让方通过询价转让受让的股份，在受让后 6 个月内不得转让； 本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投资 者。 一、拟参与转让的股东情况 （一）出让方的名称、持股数量、持股比例 出让方委托中国国际金融股份有限公司（以下简称"中金公司"）组织实施 本次询价转让。截至 2025 年 ...

中国国际金融股份有限公司 关于科兴生物制药股份有限公司 股东向特定机构投资者询价转让股份 相关资格的核查意见 中国国际金融股份有限公司（以下简称"中金公司"）受科兴生物制药股份有限 公司（以下简称"科兴制药"）股东深圳科益医药控股有限公司（以下简称"深圳科 益""出让方"）委托，组织实施本次科兴制药股东向特定机构投资者询价转让（以 下简称"本次询价转让"）。 根据《关于在上海证券交易所设立科创板并试点注册制的实施意见》《科创板上 市公司持续监管办法（试行）》《上海证券交易所科创板股票上市规则》《上海证券 交易所科创板上市公司自律监管指引第 4 号——询价转让和配售》（以下简称"《询 价转让和配售指引》"）等相关规定，中金公司对参与本次询价出让方的相关资格进 行了核查。 本次询价转让的委托情况、出让方相关资格的核查情况及核查意见如下： 一、本次询价转让的委托 中金公司已收到出让方关于本次询价转让的委托，委托中金公司组织实施本次询 价转让。 二、关于参与本次询价转让股东相关资格的核查情况 （一）核查过程 根据相关法规要求，中金公司已完成出让方相关资格的核查工作，包括核查出让 方提供的营业执照、《承诺及声明函》等， ...

Group 1 - The core point of the article is that Sinovac Biotech (688136.SH) has announced a shareholder inquiry transfer plan, where Shenzhen Koyi Pharmaceutical Holdings Co., Ltd. intends to transfer a total of 10.0628 million shares, representing 5.00% of the company's total share capital [1]